Research programme: monoclonal antibody therapeutics - Morphotek/NIAID

Drug Profile

Research programme: monoclonal antibody therapeutics - Morphotek/NIAID

Latest Information Update: 25 May 2010

Price : $50

At a glance

  • Originator Morphotek
  • Developer Morphotek; National Institute of Allergy and Infectious Diseases
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Infections

Most Recent Events

  • 26 Sep 2008 Morphotek Inc enter into an agreement to access Pivotal BioScience's LEC platform technology for the development of therapeutic monoclonal antibodies
  • 22 May 2008 Preclinical trials in Infections in USA (Parenteral)
  • 22 May 2008 Morphotek establishes CRADA with National Institute of Allergy and Infectious Diseases (NIAID) for the development of monoclonal antibodies in Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top